News

COVID-19 Information 2021.04.30

Toward the Development of COVID-19 Therapeutic Agent using Bonac Nucleic Acid: Contract Research and Development Agreement with Japan Agency for Medical Research and Development (AMED) and Creation of Innovation for Clinical Empowerment (CiCLE)

Bonac Corporation announced a joint press conference with Fukuoka Prefecture regarding the contract agreement with the Japan Agency for Medical Research and Development (AMED) and Cyclic Innovation for Clinical Empowerment (CiCLE) for the research and development of therapeutic agents for SARS-CoV-2 infection, which has been conducted in collaboration with the Fukuoka Institute of Health and Environmental Sciences.

 

At the press conference, Governor Hattori stated, "I believe that the development of therapeutic drugs will make further progress now that the project has been adopted as a national project. For the sake of patients suffering from COVID-19, we will continue to work together with related parties to develop this therapeutic."

 

Bonac will continue to work together with Fukuoka Prefecture to deliver the therapeutic drug to patients as soon as possible.

Joint press conference

Contact:

Corporate Affairs

press@bonac.co.jp

Studies in Development of Nucleic Acid Technology-Based COVID-19 Treatment to Gain Momentum with Government Subsidy

Back to News List

  • Toward the Development of COVID-19 Therapeutic Agent using Bonac Nucleic Acid: Contract Research and Development Agreement with Japan Agency for Medical Research and Development (AMED) and Creation of Innovation for Clinical Empowerment (CiCLE)

ページ上部へ